|
|
Volumn 3, Issue 4, 2011, Pages
|
|
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany
a
|
|
Author keywords
Antibody drug conjugates; Brentuximab vedotin; Cancer; Immunoconjugates; Inotuzumab ozogamicin; Oncology; Trastuzumab emtansine
|
|
Indexed keywords
2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE;
ALPHARADIN;
ANTIBODY CONJUGATE;
ANTINEOPLASTIC AGENT;
BRENTUXIMAB VEDOTIN;
BT 062;
CAPECITABINE;
CDX 011;
DOCETAXEL;
DUOCARMYCIN DERIVATIVE;
FLUOROURACIL;
GDC 0980;
GEMTUZUMAB OZOGAMICIN;
INOTUZUMAB OZOGAMICIN;
LAPATINIB;
LENALIDOMIDE;
NAVELBINE;
PERTUZUMAB;
RITUXIMAB;
TRASTUZUMAB EMTANSINE;
UNCLASSIFIED DRUG;
CAC10 VCMMAE;
CAC10-VCMMAE;
DRUG DERIVATIVE;
MAYTANSINE;
MONOCLONAL ANTIBODY;
TRASTUZUMAB DM1 CONJUGATE;
TRASTUZUMAB-DM1 CONJUGATE;
ALOPECIA;
ANTIBODY SPECIFICITY;
ANTINEOPLASTIC ACTIVITY;
BONE MARROW SUPPRESSION;
CONFERENCE PAPER;
CYTOTOXICITY;
DIARRHEA;
DRUG DOSE ESCALATION;
DRUG HALF LIFE;
DRUG POTENTIATION;
DRUG RESEARCH;
EUROPE;
FATIGUE;
FEVER;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LOADING DRUG DOSE;
NAUSEA;
NEUTROPENIA;
SIDE EFFECT;
THROMBOCYTOPENIA;
BIOTECHNOLOGY;
CHEMISTRY;
CLINICAL TRIAL (TOPIC);
IMMUNOLOGY;
IMMUNOTHERAPY;
NEOPLASM;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
BIOTECHNOLOGY;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOCONJUGATES;
IMMUNOTHERAPY;
MAYTANSINE;
NEOPLASMS;
|
|
EID: 79960097846
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.3.4.16612 Document Type: Conference Paper |
|
Times cited : (27)
|
|
References (0)
|
